While data and pregnancy outcomes are well established, previous data published on sickle cell trait and pregnancy outcomes have been controversial with some reports showing a significant association with preeclampsia. Our study aims to evaluate the risk of adverse pregnancy outcomes in pregnant patients with sickle cell trait who underwent prenatal care at our tertiary-care institution.
Database obtained from LabCorp of all patients from the Regional One Health Outpatient Clinic who underwent hemoglobin electrophoresis obtained from July 2012 to April 2013. Chart review was performed to collect medical history, laboratory data, delivery information and pregnancy outcomes. Data were analyzed with SPSS Version 22 software. ANOVA, chi-square test and Bonferroni correction test were used where applicable.
Of 350 patients, 102 were excluded for lack of delivery information, multiple gestation, and delivery less than 20 weeks. A comparison of 223 patients with normal hemoglobin and 16 patients with HbAS showed no statistically significant difference in pregnancy outcomes including Preeclampsia or HELLP Syndrome, gestational hypertension, fetal growth restriction, preterm delivery, gestational diabetes, premature rupture of membranes or cesarean delivery. Furthermore, in our cohort, there was no increased risk of bacteriuria diagnosed in the outpatient setting. A subanalysis of patients with HbAS who tested positive for bacteriuria failed to show increased risk for fetal growth restriction.
In our cohort, carriers of HbAS are not at increased risk for adverse pregnancy outcomes or bacteriuria. Fetal growth restriction was not more prevalent in our cohort even in women with bacteriuria when compared to controls.
University of Tennessee OBGYN Residency, Memphis, TN
Financial Disclosure: The authors did not report any potential conflicts of interest.